跳转至内容
Merck
所有图片(1)

文件

D-047

Supelco

N-去甲基西酞普兰盐酸盐 盐酸盐 溶液

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

别名:

N-去甲基西酞普兰盐酸盐 盐酸盐 溶液

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C19H19FN2O · HCl
CAS号:
144025-14-9
分子量:
346.83
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

certified reference material

品質等級

300

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

濃度

1.0 mg/mL in methanol (as free base)

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

格式

single component solution

儲存溫度

−20°C

InChI

1S/C19H19FN2O/c1-22-10-2-9-19(16-4-6-17(20)7-5-16)18-8-3-14(12-21)11-15(18)13-23-19/h3-8,11,22H,2,9-10,13H2,1H3/t19-/m0/s1

InChI 密鑰

PTJADDMMFYXMMG-IBGZPJMESA-N

相关类别

一般說明

N-去甲基西酞普兰是SSRI抗抑郁药西酞普兰的一种活性代谢产物。西酞普兰在美国和加拿大以Celexa®的名义进行销售，可用于治疗与情绪障碍相关的重度抑郁症。

應用


  • Reference concentrations for forensic and clinical toxicology:N-Desmethylcitalopram hydrochloride is used as a reference compound in neuropharmacological and toxicological studies (Nedahl et al., 2018).

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Celexa is a registered trademark of H. Lundbeck A/S
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes,Central nervous system

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

49.5 °F - closed cup

閃點（°C）

9.7 °C - closed cup

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Francesca-Maria Raffaelli et al.
Scientific reports, 10(1), 20203-20203 (2020-11-21)
Brown adipose tissue (BAT) thermogenesis is considered a potential target for treatment of obesity and diabetes. In vitro data suggest dopamine receptor signaling as a promising approach; however, the biological relevance of dopamine receptors in the direct activation of BAT
Lili Aslostovar et al.
Cell reports. Medicine, 2(2), 100202-100202 (2021-03-06)
The aberrant expression of dopamine receptors (DRDs) in acute myeloid leukemia (AML) cells has encouraged the repurposing of DRD antagonists such as thioridazine (TDZ) as anti-leukemic agents. Here, we access patient cells from a Phase I dose escalation trial to

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门